Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity
Abstract Background Increased glucagon levels are now recognized as a pathophysiological adaptation to counteract overnutrition in type 2 diabetes (T2D). This study aimed to elucidate the role of glucagon in peripheral nerve function in patients with T2D with different body mass indices (BMIs). Meth...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-025-01601-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571461226725376 |
|---|---|
| author | Hao Hua Rui Wang Yu-xian Xu Feng Xu Chun-hua Wang Li-hua Zhao Li-hua Wang Cheng-wei Duan Jian-bin Su |
| author_facet | Hao Hua Rui Wang Yu-xian Xu Feng Xu Chun-hua Wang Li-hua Zhao Li-hua Wang Cheng-wei Duan Jian-bin Su |
| author_sort | Hao Hua |
| collection | DOAJ |
| description | Abstract Background Increased glucagon levels are now recognized as a pathophysiological adaptation to counteract overnutrition in type 2 diabetes (T2D). This study aimed to elucidate the role of glucagon in peripheral nerve function in patients with T2D with different body mass indices (BMIs). Methods We consecutively enrolled 174 individuals with T2D and obesity (T2D/OB, BMI ≥ 28 kg/m2), and 480 individuals with T2D and nonobesity (T2D/non-OB, BMI < 28 kg/m2), all of whom underwent oral glucose tolerance tests to determine the area under the curve for glucagon (AUCgla). Electromyography was utilized to assess overall composite Z-scores for latency, amplitude, and nerve conduction velocity (NCV) across all peripheral nerves, specifically examining the median, ulnar, common peroneal, posterior tibial, superficial peroneal, and sural nerves. Results In the T2D/OB group, the AUCgla exhibited a significant correlation with the latency, amplitude and NCV of each peripheral nerve, as well as with the overall composite Z-scores for latency (r = –0.283, p < 0.001), amplitude (r = 0.295, p < 0.001), and NCV (r = 0.362, p < 0.001). In contrast, the T2D/non-OB group did not exhibit obvious correlations between the AUCgla and the overall composite Z-scores for latency (r = –0.088, p = 0.056), amplitude (r = 0.054, p = 0.251), and NCV (r = 0.116, p = 0.012). Furthermore, multivariate linear regression analyses indicated that elevated AUCgla was independently associated with a lower overall composite Z-score for latency (β = –0.304, t = –3.391, p = 0.001), as well as higher overall composite Z-scores for amplitude (β = 0.256, t = 2.630, p = 0.010) and NCV (β = 0.286, t = 3.503, p = 0.001), after adjusting for other clinical covariates within the T2D/OB group. Conclusion Increased glucagon levels may be a potential protective factor against peripheral nerve compromise in patients with T2D and obesity. |
| format | Article |
| id | doaj-art-93d91ded94594a73841cd427cf55b0a9 |
| institution | Kabale University |
| issn | 1758-5996 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj-art-93d91ded94594a73841cd427cf55b0a92025-02-02T12:35:11ZengBMCDiabetology & Metabolic Syndrome1758-59962025-01-0117111110.1186/s13098-025-01601-2Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesityHao Hua0Rui Wang1Yu-xian Xu2Feng Xu3Chun-hua Wang4Li-hua Zhao5Li-hua Wang6Cheng-wei Duan7Jian-bin Su8Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Nursing, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityMedical Research Center, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityDepartment of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong CityAbstract Background Increased glucagon levels are now recognized as a pathophysiological adaptation to counteract overnutrition in type 2 diabetes (T2D). This study aimed to elucidate the role of glucagon in peripheral nerve function in patients with T2D with different body mass indices (BMIs). Methods We consecutively enrolled 174 individuals with T2D and obesity (T2D/OB, BMI ≥ 28 kg/m2), and 480 individuals with T2D and nonobesity (T2D/non-OB, BMI < 28 kg/m2), all of whom underwent oral glucose tolerance tests to determine the area under the curve for glucagon (AUCgla). Electromyography was utilized to assess overall composite Z-scores for latency, amplitude, and nerve conduction velocity (NCV) across all peripheral nerves, specifically examining the median, ulnar, common peroneal, posterior tibial, superficial peroneal, and sural nerves. Results In the T2D/OB group, the AUCgla exhibited a significant correlation with the latency, amplitude and NCV of each peripheral nerve, as well as with the overall composite Z-scores for latency (r = –0.283, p < 0.001), amplitude (r = 0.295, p < 0.001), and NCV (r = 0.362, p < 0.001). In contrast, the T2D/non-OB group did not exhibit obvious correlations between the AUCgla and the overall composite Z-scores for latency (r = –0.088, p = 0.056), amplitude (r = 0.054, p = 0.251), and NCV (r = 0.116, p = 0.012). Furthermore, multivariate linear regression analyses indicated that elevated AUCgla was independently associated with a lower overall composite Z-score for latency (β = –0.304, t = –3.391, p = 0.001), as well as higher overall composite Z-scores for amplitude (β = 0.256, t = 2.630, p = 0.010) and NCV (β = 0.286, t = 3.503, p = 0.001), after adjusting for other clinical covariates within the T2D/OB group. Conclusion Increased glucagon levels may be a potential protective factor against peripheral nerve compromise in patients with T2D and obesity.https://doi.org/10.1186/s13098-025-01601-2Type 2 diabetesObesityGlucagonPeripheral nerve function |
| spellingShingle | Hao Hua Rui Wang Yu-xian Xu Feng Xu Chun-hua Wang Li-hua Zhao Li-hua Wang Cheng-wei Duan Jian-bin Su Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity Diabetology & Metabolic Syndrome Type 2 diabetes Obesity Glucagon Peripheral nerve function |
| title | Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity |
| title_full | Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity |
| title_fullStr | Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity |
| title_full_unstemmed | Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity |
| title_short | Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity |
| title_sort | glucagon a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity |
| topic | Type 2 diabetes Obesity Glucagon Peripheral nerve function |
| url | https://doi.org/10.1186/s13098-025-01601-2 |
| work_keys_str_mv | AT haohua glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT ruiwang glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT yuxianxu glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT fengxu glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT chunhuawang glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT lihuazhao glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT lihuawang glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT chengweiduan glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity AT jianbinsu glucagonapotentialprotectivefactoragainstperipheralnervecompromiseinpatientswithtype2diabetesandobesity |